← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Zalgen Labs, Llc
Germantown, MD
$10,095,661
Total funding
5
Grants
Funding over time
peak $1.9M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,095,661 · 5
By mechanism
R01$6,295,715 · 1
R44$2,856,094 · 2
R43$943,852 · 2
Investigators at Zalgen Labs, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,498,398
R01 · FY2019 · AI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,222,182
R01 · FY2020 · AI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,202,174
R01 · FY2021 · AI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,192,954
R01 · FY2022 · AI
Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies$1,180,007
R01 · FY2023 · AI
Recombinant antigen diagnostics for filoviruses$1,000,000
R44 · FY2016 · AI
Late-stage development toward commercialization of multilineage point-of-care Lassa fever diagnostics$928,504
R44 · FY2016 · AI
Late-stage development toward commercialization of multilineage point-of-care Lassa fever diagnostics$927,590
R44 · FY2015 · AI
Glycoprotein Immunoassay to Measure Protective Response to Lassa Vaccine$497,084
R43 · FY2018 · AI
Glycoprotein Immunoassay to Measure Protective Response to Lassa Vaccine$299,050
R43 · FY2019 · AI
Evaluation of fully human Pan-Old World Arenavirus monoclonal antibodies as candidate therapeutics for LCMV infection$147,718
R43 · FY2015 · AI